Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Harvard Business School
Colorcon
AstraZeneca
Johnson and Johnson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

King Pharms Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for King Pharms
International Patents:73
US Patents:6
Tradenames:25
Ingredients:23
NDAs:27

Drugs and US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-003 May 25, 2001 AB1,AB3 RX Yes No 6,555,581   See Pricing   See Pricing
King Pharms TAPAZOLE methimazole TABLET;ORAL 007517-002 Approved Prior to Jan 1, 1982 DISCN Yes No   See Pricing   See Pricing
King Pharms LORABID loracarbef FOR SUSPENSION;ORAL 050667-001 Dec 31, 1991 DISCN No No   See Pricing   See Pricing
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-008 May 25, 2001 AB1,AB3 RX Yes No 7,067,148   See Pricing Y   See Pricing
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 DISCN No No   See Pricing   See Pricing
King Pharms Llc AVINZA morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021260-002 Mar 20, 2002 DISCN No No   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 3,419,578   See Pricing
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 3,860,618   See Pricing
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 3,975,536   See Pricing
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 5,403,856   See Pricing
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 4,587,258   See Pricing
King Pharms Llc AVINZA morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021260-003 Mar 20, 2002 6,066,339   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for KING PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 800 mg ➤ Subscribe 2004-11-04
➤ Subscribe Extended-release Capsules 45 mg and 75 mg ➤ Subscribe 2009-07-30
➤ Subscribe Extended-release Capsules 30 mg, 60 mg, 90 mg and 120 mg ➤ Subscribe 2007-06-04

Supplementary Protection Certificates for King Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0265685 99C0001 Belgium   See Pricing PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
0265685 C980030 Netherlands   See Pricing PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
1539166 2013/055 Ireland   See Pricing PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
1539166 2013C/064 Belgium   See Pricing PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626
0265685 SPC/GB98/047 United Kingdom   See Pricing PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
1539166 13C0062 France   See Pricing PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Boehringer Ingelheim
Moodys
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.